LuciAlpe — Alpelisib 150 mg, 28 pcs, Lucius

LuciAlpe — Alpelisib Tablets 150 mg, 28 Tablets

Product code: 493

15198₴ 16539₴ -8% On order · from 10 days

Analogues

Alpesib LuciAlpe
1
Active ingredient
Dosage
150 mg
Dosage form Tablets
Tablets per pack 28

LuciAlpe is an advanced targeted antineoplastic agent belonging to the phosphatidylinositol 3-kinase (PI3K) inhibitor class, indicated for the treatment of hormone-dependent breast cancers. The active pharmaceutical ingredient is alpelisib at a strength of 150 mg supplied as film-coated oral tablets (Alpelisib Tablets 150 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Alpelisib is a specific inhibitor of the alpha-isoform of phosphatidylinositol 3-kinase (PI3Kα), which frequently undergoes activating mutations (specifically in the PIK3CA gene) in breast cancer. Activation of the PI3K/AKT signaling pathway drives tumor growth, glucose metabolism, and endocrine therapy resistance. Inhibiting PI3Kα with alpelisib restores tumor cell sensitivity to hormone therapy. Alpelisib is administered in combination with an aromatase inhibitor (fulvestrant) in postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer harboring PIK3CA mutations.

Supplied in a package containing 28 tablets of 150 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciAlpe 150 mg:

  • ✅ Targeted Action (PI3Kα Inhibitor): Selective suppression of mutant PIK3CA pathways in breast cancer.
  • ✅ Overcoming Resistance: Restores tumor sensitivity to endocrine therapy when combined with fulvestrant.
  • ✅ Proven Efficacy: Extends progression-free survival in patients with HR+/HER2- metastatic breast cancer harboring PIK3CA mutations.
  • ✅ Convenient Oral Dosing: Daily administration in tablet form.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Piqray).

LuciAlpe is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Alpelisib — 150 mg.
  • Excipients: Microcrystalline cellulose, crospovidone, hypromellose, magnesium stearate, colloidal anhydrous silica, titanium dioxide, polyethylene glycol, iron oxide red/yellow (coating dependent).

Packaging and Presentation: Film-coated tablets of specific shape and color. Each package contains 28 tablets (150 mg) along with prescribing information. Labeled with LuciAlpe (Alpelisib Tablets 150 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Alpelisib is an oral alpha-specific inhibitor of class I PI3K (phosphatidylinositol 3-kinases) with highest activity against PI3Kα. Activating mutations in the PIK3CA gene lead to PI3Kα hyperactivity and AKT activation, stimulating tumor cell proliferation. Inhibition of PI3Kα by alpelisib suppresses downstream PI3K signaling, inducing cell cycle arrest and apoptosis in HR-positive breast cancer cell lines harboring PIK3CA mutations.

Pharmacokinetics:

  • Absorption: Rapidly absorbed following oral ingestion. Median time to peak plasma concentration (Tmax) ranges from 2 to 4 hours. Administration with food significantly increases bioavailability and systemic exposure (must always be taken with food!).
  • Distribution: Human plasma protein binding is approximately 89% and is concentration-independent.
  • Metabolism: Metabolized primarily via chemical/enzymatic hydrolysis into the inactive metabolite BQY790, alongside CYP3A4-mediated oxidation.
  • Elimination: Excreted predominantly via feces (approx. 810% as metabolites and unchanged drug) and renally (approx. 14%). Terminal elimination half-life (T1/2) averages 11 to 12 hours.

LuciAlpe is indicated in adult patients for:

  • Breast Cancer: In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative), advanced or metastatic breast cancer harboring a PIK3CA mutation, following disease progression on or after endocrine-based therapy.

LuciAlpe is administered orally once daily, every day at approximately the same time.

Dosing Regimen:
The recommended standard dose is 300 mg (two 150 mg tablets) once daily. Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.

Administration Guidelines:
Tablets should be taken immediately after food (with a meal or snack) with a glass of water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, take the next dose the following day at the usual scheduled time (do not take a double dose to make up for a missed dose).

Administration of LuciAlpe is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to alpelisib or any excipient.
  • Severe Diabetes Mellitus: Severe forms of uncontrolled or decompensated diabetes mellitus (due to severe hyperglycemia risks).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women due to high teratogenic risks.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.

Alpelisib is metabolized by enzymes and interacts with specific transporter pathways:

  • CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): May significantly decrease alpelisib plasma concentrations and reduce efficacy. Avoid concurrent use.
  • BCRP Inhibitors (efflux transporters): May increase systemic exposure to alpelisib.
  • Hyperglycemic Agents: Because alpelisib frequently causes hyperglycemia, caution is warranted when co-administered with other medications that elevate blood glucose levels.

Pregnancy:
LuciAlpe is contraindicated during pregnancy. Based on its mechanism of action and preclinical animal findings, alpelisib can cause fetal harm when administered to pregnant women. Females of reproductive potential must utilize effective non-hormonal contraception during treatment and for at least 1 week following the final dose.

Lactation:
Excretion into human breast milk is unknown. Breastfeeding must be discontinued during treatment and for 1 week post-therapy.

The most frequent and clinically significant adverse reactions include:

  • Glucose Metabolism Disorders (Very Common): Hyperglycemia (elevated blood glucose levels), requiring rigorous blood sugar monitoring and initiation of antidiabetic therapy when clinically indicated.
  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, decreased appetite, stomatitis, abdominal pain.
  • Dermatologic Reactions: Rash (including severe cutaneous adverse reactions such as erythema multiforme or Stevens-Johnson syndrome), pruritus, dry skin.
  • Hematologic Toxicity: Lymphopenia, anemia, thrombocytopenia.
  • General Disorders: Fatigue, weight loss, hypocalcemia, elevations in serum creatinine and liver transaminases.

Symptoms:
Specific acute overdose symptoms of alpelisib are not established. Anticipated manifestations include exacerbation of hyperglycemia, nausea, diarrhea, and skin rashes.

Treatment:
No specific antidote exists. In case of overdose, discontinue treatment, monitor the patient closely, and provide supportive and symptomatic care (including blood glucose management).

Storage Requirements for LuciAlpe 150 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Do not use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciAlpe 150 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics and Alpelisib Tablets 150 mg.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00